Showing 5531-5540 of 6808 results for "".
- Rihanna Introduces Fenty Skinhttps://practicaldermatology.com/news/rihanna-introduces-fenty-skin/2460487/Rihanna, in partnership with Kendo Brands, is rolling out Fenty Skin. After years of feeling overwhelmed by all the skincare choices and a bad experience with a product that discolored her skin as a teen, Rihanna dreamed of creating a line that was easy and effective. Now, she'
- Industry Responds to COVID-19: Cyrex Labs Offers Multiple Autoimmune Reactivity Screenhttps://practicaldermatology.com/news/industry-responds-to-covid-19-pyrex-labs-offers-multiple-autoimmune-reactivity-screen/2460484/With the risks associated with COVID-19 and because those with one autoimmune disease have a 25 percent chance of developing another, specialists say it is critical for those with autoimmune disease to use safety measures, good eating habits, and self-care to avoid contracting this or any virus.&
- Genentech’s Tecentriq plus Cotellic and Zelboraf Approved for Advanced Melanomahttps://practicaldermatology.com/news/genentechs-tecentriq-plus-cotellic-and-zelboraf-approved-for-advanced-melanoma/2460483/Tecentriq (atezolizumab) is now approved in combination with Cotellic (cobimetinib) and Zelboraf(vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profil
- Stelara Approved for PsO in Kids Ages 6-11https://practicaldermatology.com/news/stelara-approved-for-pso-in-kids-ages-6-11/2460482/Stelara® (ustekinumab) is now approved for pediatric patients (6-11 years of age) with moderate to severe plaque psoriasis (PsO). Stelara, from The Janssen Pharmaceutical Companies of Johnson & Johnson, targets both interleukin (IL)-12 and IL-23
- George W. Mahaffey Named CEO of Mindera Corporationhttps://practicaldermatology.com/news/george-w-mahaffey-named-ceo-of-mindera-corporation/2460480/George W. Mahaffey is the new President and Chief Executive Officer of Mindera Corporation. He will also serve as a Director of the Company. Mindera has developed a novel platform to extract thousands of biomarkers from an individual patient via a dermal biomarker patch. Captured R
- Win for MC2 Therapeutics: Wynzora Cream Approved for Adults with Psoriasishttps://practicaldermatology.com/news/win-for-mc2-therapeutics-wynzora-cream-approved-for-adults-with-psoriasis/2460476/FDA has approved Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. The approval is based on results of the US Phase 3 clinical trial&nbs
- Abbvie's Rinvoq Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitishttps://practicaldermatology.com/news/abbvies-rinvoq-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase-3-study-for-atopic-dermatitis/2460475/AbbVie's upadacitinib (Rinvoq) (15 mg and 30 mg, once daily) monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis. The co-primary endpoints were at least a 75 percent improvement in the Ecze
- Another New Patent for Alastin Skincarehttps://practicaldermatology.com/news/another-new-patent-for-alastin-skincare/2460473/Alastin Skincare, Inc. received a fourth U.S. Patent from the United States Patent and Trademark Office. The new patent, which incorporates TriHex Technology, is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Arcutis Initiates Patient Enrollment in Phase 2b Study in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-initiates-patient-enrollment-in-phase-2b-study-in-chronic-hand-eczema/2460466/Arcutis Biotherapeutics, Inc. initiated enrollment in the Phase 2b portion of the Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1), in adult patients with chronic hand eczema. Topline data from this trial are expected in the